Pfizer Inc. (NYSE:PFE) on Tuesday reported better-than-expected first-quarter results and reaffirmed its 2026 financial guidance.

This positive momentum comes alongside a broader market environment where S&P 500 futures are gaining by 0.4%, suggesting a favorable tone for equities overall.

Pfizer Q1 Results And 2026 Guidance Reaffirmation

The U.S. pharma giant adjusted earnings of 75 cents, beating the Wall Street estimate of 72 cents.

Sales jumped 5% year over year to $14.45 billion, beating the consensus of $13.79 billion.

The operational increase was primarily driven by an increase in revenues for Padcev, Eliquis, Oncology biosimilars, Nurtec, and several other products across categories, partially offset by a year-over-year decline in COVID-19 product revenues.

Read Also:

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

Leadership Highlights Pipeline And Commercial Strength

“We’re off to a strong start in 2026…Our R&D pipeline is advancing on multiple fronts, with positive Phase 3 readouts and encouraging mid-stage ...